Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

SciClone Pharma (6600 HK): GL Capital Consortium Reload?

SciClone Pharma (6600 HK): Privatisation At IPO Price

SciClone Pharmaceuticals (6600 HK): 19th June Shareholder Vote

SciClone (赛生药业) IPO: A Mediocre Deal

SciClone Pharmaceuticals IPO Valuation: Not Pleasing

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

New Horizon Health IPO Trading Update: A Blockbuster IPO but It’s Time You Plan an Exit Strategy

Quiddity Advisors

Event-Driven

<ul>
<li>Shareholders have given <strong><a href="https://www.smartkarma.com/entities/sciclone-pharmaceuticals-holdings-limited" target="_blank" data-smartkarma-citation="entities:17351:1" rel="noopener">SciClone Pharmaceuticals (6600 HK)</a></strong>'s buyback the go-ahead which will result in the major shareholder holding (upward of) 31.63%, and the freedom to creep.</li>
<li>As such, a concentrated shareholder register, primarily comprising entities that privatised SciClone in 2017, gets even more concentrated.</li>
<li>Trading inexpensively ahead of the launch of a new (and approved) drug, SciClone is worth a second look. </li>
</ul>


Shareholders have given SciClone Pharmaceuticals (6600 HK)'s buyback the go-ahead which will result in the major shareholder holding (upward of) 31.63%, and the freedom to creep.
As such, a concentrated shareholder register, primarily comprising entities that privatised SciClone in 2017, gets even more concentrated.
Trading inexpensively ahead of the launch of a new (and approved) drug, SciClone is worth a second look. 


SciClone Pharma (6600 HK): Inexpensive Ahead Of New Therapies Rolling Out

Sciclone Pharmaceuticals

SciClone Pharma (6600 HK): Inexpensive Ahead Of New Therapies Rolling Out